Neuroplasticity in the Aging Brain: Mechanisms and Therapeutic Implications
2Center for Aging Research, Harvard Medical School, Boston, MA 02115, USA
3Institute of Neurology, Stanford University, Stanford, CA 94305, USA
Abstract
Neuroplasticity, the brain’s capacity to reorganize its structure and function in response to experience or injury, declines with age but remains a critical factor in maintaining cognitive health. This review synthesizes recent findings on the molecular, cellular, and systems-level mechanisms underlying neuroplasticity in the aging brain. We discuss age-related changes in synaptic plasticity, neurogenesis, and glial support, highlighting the roles of inflammation, oxidative stress, and epigenetic modifications. Therapeutic strategies, including pharmacological interventions (e.g., NMDA receptor modulators), cognitive training, and lifestyle modifications, are evaluated for their efficacy in enhancing plasticity. Evidence from rodent models, human neuroimaging, and longitudinal cohort studies supports targeted interventions to mitigate cognitive decline. Future directions emphasize personalized medicine approaches leveraging biomarkers of plasticity.
Keywords: neuroplasticity, aging, synaptic remodeling, neurogenesis, cognitive reserve, therapeutics
Introduction
The human brain exhibits remarkable plasticity throughout life, enabling adaptation to environmental demands and recovery from insults. However, aging is associated with a progressive decline in neuroplasticity, contributing to cognitive impairments such as memory loss and executive dysfunction (Bishop et al., 2010). Understanding the mechanisms of plasticity in the aging brain is essential for developing interventions to promote healthy aging.
Historically, the adult brain was considered post-mitotic, with limited capacity for structural change. Landmark discoveries, including adult neurogenesis in the hippocampus (Eriksson et al., 1998) and experience-dependent synaptogenesis (Woolf, 2005), revolutionized this view. In aging, plasticity persists but is attenuated, influenced by factors such as reduced neurotrophic support and chronic low-grade inflammation (“inflammaging”; Franceschi et al., 2018).
Mechanisms of Neuroplasticity in Aging
Synaptic Plasticity
Synaptic plasticity, encompassing long-term potentiation (LTP) and long-term depression (LTD), is foundational to learning and memory. Aging impairs LTP induction due to altered NMDA and AMPA receptor trafficking (Barnes, 2003). Calcium dysregulation and enhanced GABAergic inhibition further contribute to this deficit (Pannese, 2011).
Neurogenesis and Structural Remodeling
Hippocampal neurogenesis declines sharply after midlife, correlating with spatial memory impairments (Lazarov et al., 2010). Dendritic spine density decreases in prefrontal and hippocampal regions, linked to reduced BDNF signaling (Angelucci et al., 2004).
Glial Contributions
Microglia and astrocytes modulate plasticity. Senescent microglia promote neuroinflammation via cytokine release (e.g., IL-1β, TNF-α), while astrocytic glutamate uptake diminishes (Rodriguez-Arellano et al., 2016).
Therapeutic Interventions
Pharmacological Approaches
Drugs enhancing plasticity include memantine (NMDA antagonist) and SSRIs, which upregulate BDNF (Maya Vetencourt et al., 2008). Recent trials with rapalogs (mTOR inhibitors) show promise in restoring LTP (Caccamo et al., 2010).

Non-Pharmacological Strategies
Aerobic exercise boosts neurogenesis via VEGF and IGF-1 (Voss et al., 2011). Cognitive training and environmental enrichment enhance dendritic arborization in rodents (Kempermann et al., 2010).
| Intervention | Mechanism | Evidence Level | Clinical Outcomes |
|---|---|---|---|
| Aerobic Exercise | Increases BDNF, neurogenesis | Meta-analysis (n=20 studies) | Improved executive function |
| Memantine | NMDA modulation | RCT (Phase III) | Modest memory gains |
| Cognitive Training | Synaptic strengthening | Longitudinal cohort | Delayed decline |
Discussion
While aging attenuates neuroplasticity, multifaceted interventions can partially restore it. Challenges include heterogeneity in aging trajectories and translating animal findings to humans. Biomarkers such as plasma BDNF levels and fMRI plasticity indices offer promise for stratification (Klein et al., 2019). Personalized therapies, informed by genetics (e.g., APOE status), represent the next frontier.
Conclusion
Harnessing neuroplasticity holds transformative potential for aging-related cognitive disorders. Integrated research across scales will accelerate clinical translation.
Acknowledgments
This work was supported by NIH grants AG045123 and NS078900.
Conflicts of Interest
The authors declare no conflicts of interest.
References
Related Resource: Gul
